Conference Correspondent

Checkmate 017: A Phase 3 Study of Nivolumab vs Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

Final Overall Survival Results of the Phase 3 PROCLAIM Trial

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

Necitumumab in Metastatic Squamous NSCLC: Establishing a Value-Based Cost

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

Phase 1-1B Trial of Tivantinib in Combination with Carboplatin and Pemetrexed as First-Line Treatment in Patients with Advanced Nonsquamous NSCLC or Malignant Pleural Mesothelioma

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

A Phase 3B/4 Safety Trial of Nivolumab (NIVO) in Patients with Advanced or Metastatic NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

Phase 3 Trial (Checkmate 057) of Nivolumab (NIVO) Versus Docetaxel (DOC) In Advanced Non Squamous Cell (Non-SQ) NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent — May 28, 2015

Safety Overview of the CLLM1 Trial: Lenalidomide Maintenance Therapy After Frontline Chemoimmunotherapy in High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Functional Evidence that Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

The Combination of Alemtuzumab and Ofatumumab in Previously Untreated CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Ublituximab plus TGR-1202 in Heavily Pretreated and High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Page 31 of 44

28
29
30
31
32
33
34